This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Influenza virus	Influenza A virus hemagglutinin (HA)	<i>In vitro</i> and mouse studies suggest the HA-targeting mAb CO5 could help prevent or treat influenza infection. <i>In vitro</i> , CO5 neutralized influenza virus subtypes H1, H2, H3 and H9 by binding the HA globular head domain rather than the stem region targeted by most broadly neutralizing antibodies. In mouse models of H1N1 and H3N2 influenza virus infection, CO5 given 24 hours before lethal challenge resulted in 100% survival. In the same models, CO5 given up to 3 days after infection also resulted in 100% survival. Ongoing work includes developing stable cell line production of the antibody.	Covered by issued and pending patents; available for licensing	Ekiert, D.C. <i>et al. Nature</i> ; published online Sept. 16, 2012; doi:10.1038/nature11414 Contact: Ian A. Wilson, The Scripps Research Institute, La Jolla, Calif. e-mail: wilson@scripps.edu Contact: Ramesh R. Bhatt, Sea Lane Biotechnologies LLC, Mountain View, Calif. e-mail: ramesh.bhatt@sealanebio.com
SciBX 5(38); doi:10.1038/scibx.2012.1009 Published online Sept. 27, 2012				